secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2025-06-24T23:59:59+00:00
Accession:  0001213900-25-056908
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEO Steve Silvestro appointed to OptimizeRx Board effective June 20, 2025
-------------------------------------------------------------------------

- Board increased to six members and appointed CEO Stephen Silvestro as director.
- Silvestro has served as CEO since March 2025, previously interim CEO from January 2025.
- Appointment effective through the 2026 annual meeting; no financial impact disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390025056908/0001213900-25-056908-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390025056908/ea0246602-8k_optimize.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-056908

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer